

Alba Ariela Brandes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3594538/alba-ariela-brandes-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

242
papers

37,025
citations

67
h-index

192
g-index

276
ext. papers

43,091
ext. citations

6.1
avg, IF

6.39
L-index

#	Paper	IF	Citations
242	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. <i>Cancers</i> , 2022 , 14,	6.6	1
241	Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.. <i>Acta Neuropathologica Communications</i> , 2022 , 10, 1	7.3	4
240	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.. <i>Frontiers in Oncology</i> , 2022 , 12, 852950	5.3	4
239	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022 , 82, 491	12.1	2
238	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <i>Neuro-Oncology</i> , 2022 ,	1	6
237	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1333-1353	3.5	4
236	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , 2021 ,	3.8	2
235	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021 , 3, e784-e794	14.4	6
234	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , 2021 , 11,	3.8	2
233	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021 , 13, 419-432	3.8	3
232	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , 2021 , 3008916211017213	1.7	0
231	IDH1 single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , 2021 , 221, 153445	3.4	2
230	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , 2021 , 221, 153447	3.4	1
229	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 457-473	4.5	3
228	Molecular alterations in pancreatic tumors. <i>World Journal of Gastroenterology</i> , 2021 , 27, 2710-2726	5.6	4
227	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021 , 26, 865-878	5.7	7
226	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , 2021 , 10, CNS72	4	6

225	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology, The</i> , 2021 , 22, 813-823	21.7	24
224	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021 , 13,	6.6	5
223	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021 , 11,	3.8	6
222	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021 , 145, 171-178	7.5	3
221	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021 , 41, 757-773	3.2	0
220	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04604	0.7	0
219	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , 2021 , 33,	2.4	1
218	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1265-1272	3.5	1
217	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 1185-1194	5.1	0
216	Is There a Role for Surgical Resection of Multifocal Glioblastoma? A Retrospective Analysis of 100 Patients. <i>Neurosurgery</i> , 2021 , 89, 1042-1051	3.2	0
215	Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1003-1010	13.4	328
214	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology, The</i> , 2020 , 21, e317- e329	21.7	31
213	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. <i>Diagnostics</i> , 2020 , 10,	3.8	4
212	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , 2020 , 16, 1053-1063	3.6	10
211	Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2020 , 149, 65-71	4.8	4
210	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020 , 16, 1433-1439	3.6	8
209	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa147	0.9	1
208	Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. <i>Neuro-Oncology Practice</i> , 2020 , 7, 668-675	2.2	2

207	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020 , 9, 8373-8385	4.8	7
206	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. <i>European Journal of Cancer</i> , 2020 , 137, 10-17	7.5	9
205	Glioneuronal tumors: clinicopathological findings and treatment options. <i>Future Neurology</i> , 2020 , 15, FNL47	1.5	2
204	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020 , 10, 996	5.3	4
203	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 785-795	3.5	13
202	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. <i>Future Oncology</i> , 2019 , 15, 2595-2601	3.6	3
201	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019 , 116, 190-198	7.5	11
200	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019 , 92, e2754-e2763	6.5	6
199	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. <i>Child Nervous System</i> , 2019 , 35, 2279-2287	1.7	3
198	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019 , 21, 1447-1457	1	19
197	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. <i>Oncologist</i> , 2019 , 24, 664-670	5.7	2
196	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology, The</i> , 2019 , 20, e715-e728	21.7	31
195	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 110-119	21.7	116
194	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019 , 24, 521-528	5.7	28
193	Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 383-388	4.8	9
192	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. <i>World Neurosurgery</i> , 2018 , 112, e342-e347	2.1	26
191	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018 , 135, 601-615	14.3	54
190	The burden of oncology promises not kept in glioblastoma. <i>Future Neurology</i> , 2018 , 13, 1-4	1.5	3

189	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018 , 20, 13-23	3.1	43
188	The Risk Assessment in Low-Grade Gliomas: An Analysis of the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria. <i>Oncology and Therapy</i> , 2018 , 6, 105-108	2.7	4
187	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. <i>Future Oncology</i> , 2018 , 14, 1063-1069	3.1	7
186	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018 , 14, 1559-1567	3.6	15
185	Role of Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. <i>Oncologist</i> , 2017 , 22, 432-437	5.7	43
184	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017 , 19, 625-635	1	87
183	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 1542-1552	1	78
182	Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1027-1037	59.2	525
181	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O-Methylguanine-DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017 , 35, 343-351	2.2	77
180	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRVIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1373-1385	21.7	518
179	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. <i>Journal of Neuro-Oncology</i> , 2017 , 135, 245-254	4.8	16
178	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017 , 390, 1645-1653	40	225
177	Immunotherapy in head and neck cancer: evidence and perspectives. <i>Immunotherapy</i> , 2017 , 9, 1351-1358	3.8	13
176	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1954-1963	59.2	425
175	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017 , 31, 675-684	6.7	19
174	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	20
173	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 55575-55581	3.3	9
172	The role of gender in glioblastoma: does it matter?. <i>Future Neurology</i> , 2016 , 11, 197-199	1.5	1

171	Nitrosoureas in the Management of Malignant Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016 , 16, 13	6.6	32
170	Patient outcomes following second surgery for recurrent glioblastoma. <i>Future Oncology</i> , 2016 , 12, 1039-44	3.4	21
169	Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. <i>Journal of Neuro-Oncology</i> , 2016 , 128, 157-162	4.8	21
168	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1146-56 ¹	5.6	135
167	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 115-20	3.5	22
166	EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2001-2001	2.2	34
165	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2019-2019	2.2	11
164	Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2020-2020	2.2	1
163	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA2-LBA2	2.2	12
162	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA2000-LBA2000	2.2	7
161	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA2-LBA2	2.2	24
160	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, LBA2000-LBA2000	2.2	14
159	Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma. <i>Oncotarget</i> , 2016 , 7, 55169-55180	3.3	31
158	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 33210-9	3.3	98
157	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2032-2032	2.2	
156	ACTR-01. THE ROLE OF CLINICAL CHARACTERISTICS IN LOW GRADE GLIOMAS PATIENTS IN THE ERA OF MOLECULAR BIOMARKERS: A STUDY FROM GRUPPO ITALIANO COOPERATIVO DI NEURO-ONCOLOGIA (GICNO). <i>Neuro-Oncology</i> , 2016 , 18, vi1-vi1	1	
155	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1304-12	1	53
154	Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016 , 22, 4797-4806	12.9	77

153 Adult medulloblastoma **2016**, 582-584

152 Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncology, The*, **2016**, 17, 1533-1542 21.7 77

151 Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. *Lancet Oncology, The*, **2016**, 17, 1521-1532 21.7 294

150 Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. *Current Treatment Options in Oncology*, **2016**, 17, 49 5.4 37

149 Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. *Lancet Oncology, The*, **2015**, 16, 561-8 21.7 109

148 Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. *Lancet Oncology, The*, **2015**, 16, e534-e542 21.7 425

147 Bevacizumab in recurrent glioblastoma: open issues. *Future Oncology*, **2015**, 11, 2655-2665 3.6 9

146 Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. *Journal of Clinical Pathology*, **2015**, 68, 859-69 3.9 16

145 Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. *Journal of Thoracic Oncology*, **2015**, 10, 1437-43 8.9 142

144 Post progression survival in glioblastoma: where are we?. *Journal of Neuro-Oncology*, **2015**, 121, 399-404 4.8 8

143 New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. *Critical Reviews in Oncology/Hematology*, **2015**, 94, 348-59 7 35

142 Practical management of bevacizumab-related toxicities in glioblastoma. *Oncologist*, **2015**, 20, 166-75 5.7 42

141 Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. *Journal of Clinical Oncology*, **2015**, 33, 2006-2006 2.2 7

140 A phase II study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma.. *Journal of Clinical Oncology*, **2015**, 33, 2014-2014 2.2 3

139 Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. *Journal of Clinical Oncology*, **2015**, 33, 2015-2015 2.2 22

138 Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.. *Journal of Clinical Oncology*, **2015**, 33, 2047-2047 2.2 1

137 Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, 8079-8079 2.2

136 The effect of re-operation on survival in patients with recurrent glioblastoma. *Anticancer Research*, **2015**, 35, 1743-8 2.3 35

135	Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. <i>New England Journal of Medicine</i> , 2014 , 370, 709-22	59.2	1629
134	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 1100-8	21.7	629
133	The metastatic process: a kaleidoscope of concepts. <i>Future Oncology</i> , 2014 , 10, 697-8	3.6	2
132	NI-26 * COMPARATIVE ANALYSIS OF THE RANO AND MACDONADO CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.. <i>Neuro-Oncology</i> , 2014 , 16, v143-v144	1	78
131	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. <i>PLoS ONE</i> , 2014 , 9, e103883	3.7	120
130	Shedding light on adult medulloblastoma: current management and opportunities for advances. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e82-7	7.1	13
129	Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy?. <i>Future Oncology</i> , 2014 , 10, 1137-45	3.6	16
128	The role of systemic and targeted therapies in brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 93-103	3.5	6
127	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. <i>Neuro-Oncology Practice</i> , 2014 , 1, 166-171	2.2	19
126	Resistance to antiangiogenic therapies. <i>Future Oncology</i> , 2014 , 10, 1417-25	3.6	9
125	Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 733-7	8.9	24
124	Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , 2013 , 39, 350-7	14.4	108
123	Second surgery for recurrent glioblastoma: advantages and pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 583-7	3.5	20
122	Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. <i>Future Oncology</i> , 2013 , 9, 1653-64	3.6	7
121	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. <i>Journal of Clinical Oncology</i> , 2013 , 31, 344-50	2.2	800
120	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. <i>European Journal of Cancer</i> , 2013 , 49, 2177-87	7.5	43
119	Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2005-2005	2.2	18
118	Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2007-2007	2.2	28

117	Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF- β)receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2061-2061	2.2	7
116	Final results from a large prospective Italian population study on glioblastoma and correlations with MGMT status: The Project of Emilia-Romagna Region in Neuro-oncology (PERNO).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2048-2048	2.2	
115	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology; PERNO) in newly diagnosed GBM patients (pts): Outcome analysis and correlations with MGMT methylation status in the elderly population.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2021-2021	2.2	
114	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2012 , 14, 1503-10	1	45
113	Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. <i>European Journal of Cancer</i> , 2012 , 48, 896-903	7.5	18
112	Epidemiology of glial and non-glial brain tumours in Europe. <i>European Journal of Cancer</i> , 2012 , 48, 1532-42	4.5	212
111	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. <i>European Journal of Cancer</i> , 2012 , 48, 1176-84	7.5	137
110	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 20-26	1.6	
109	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1429-35	3.5	32
108	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012 , 60, 885-94	7.3	38
107	Cytologically confirmed splenic metastases in breast cancer. <i>Future Oncology</i> , 2012 , 8, 1495-500	3.6	2
106	CNS Oncology: reflecting a rapidly changing landscape. <i>CNS Oncology</i> , 2012 , 1, 1-2	4	78
105	Anaplastic gliomas at first recurrence: Outcome analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2061-2061	2.2	1
104	Final results of a randomized, double-blind, phase II study of gemcitabine plus vandetanib or plus placebo in the treatment of advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) elderly patients (ZELIG study NCT00753714).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7550-7550	2.2	3
103	A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS2104-TPS2104	2.2	5
102	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2-2	2.2	16
101	Natural history of glioblastoma in the modern era: Longitudinal results from a large prospective Italian register.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2057-2057	2.2	
100	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2-2	2.2	

99	Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. <i>Oncology</i> , 2012 , 26, 1083-91	1.8	4
98	Medulloblastomas in adults: prognostic factors and lessons from paediatrics. <i>Current Opinion in Neurology</i> , 2011 , 24, 626-32	7.1	15
97	Primary brain tumors in the elderly population. <i>Current Treatment Options in Neurology</i> , 2011 , 13, 427-35	4.4	6
96	End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 1713-7	3.5	2
95	Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3628-35	2.2	149
94	Advances in malignant glioma drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2011 , 6, 739-53	6.2	15
93	New agents and new end points for recurrent gliomas. <i>Journal of Clinical Oncology</i> , 2011 , 29, e245-6; author reply e247	2.2	5
92	Medulloblastomas 2011 , 415-433		
91	O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. <i>Neuro-Oncology</i> , 2010 , 12, 283-8	1	99
90	Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. <i>Oncologist</i> , 2010 , 15, 683-94	5.7	32
89	EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2010 , 46, 348-54	7.5	64
88	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Clinical Cancer Research</i> , 2010 , 16, 1597-604	12.9	328
87	Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 179-84	3.5	10
86	Gangliogliomas: recent advances in classification and treatment. <i>Future Neurology</i> , 2010 , 5, 557-568	1.5	2
85	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <i>Nature Reviews Neurology</i> , 2010 , 6, 39-51	15	538
84	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. <i>BMC Cancer</i> , 2010 , 10, 48	4.8	27
83	MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5881-6	2.2	203
82	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. <i>Neuro-Oncology</i> , 2009 , 11, 737-46	1	62

81	Treatment options for recurrent glioblastoma: pitfalls and future trends. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 613-9	3.5	29
80	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1268-74	2.2	429
79	Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. <i>Cancer</i> , 2009 , 115, 3512-8	6.4	179
78	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 769-75	3.5	75
77	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 71, 165-79	7	47
76	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <i>Lung Cancer</i> , 2009 , 64, 199-206	5.9	19
75	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology, The</i> , 2009 , 10, 459-66	21.7	5111
74	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009 , 374, 1512-20	4.0	478
73	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1275-9	2.2	249
72	Treatment of recurrent high-grade gliomas. <i>Current Opinion in Neurology</i> , 2009 , 22, 657-64	7.1	22
71	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology, The</i> , 2008 , 9, 29-38	21.7	407
70	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. <i>Clinical Cancer Research</i> , 2008 , 14, 957-60	12.9	110
69	Association between response to primary treatments and MGMT status in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1781-6	3.5	5
68	Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4659-65	2.2	163
67	MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2192-7	2.2	641
66	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. <i>Neuro-Oncology</i> , 2008 , 10, 361-7	1	188
65	Chemotherapy in breast cancer patients with brain metastases: have new chemotherapeutic agents changed the clinical outcome?. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 68, 212-21	7	27
64	Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008 , 89, 179-85	4.8	73

63	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 139-52	7	126
62	Long-term results of a prospective study on the treatment of medulloblastoma in adults. <i>Cancer</i> , 2007 , 110, 2035-41	6.4	98
61	Prognostic factors for anaplastic astrocytomas. <i>Journal of Neuro-Oncology</i> , 2007 , 81, 295-303	4.8	29
60	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>British Journal of Cancer</i> , 2007 , 96, 1047-51	8.7	156
59	Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5723-30	2.2	85
58	Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5731-7	2.2	59
57	Glioblastoma in the elderly: current and future trends. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 256-66	7	34
56	Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2563-9	2.2	377
55	Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4746-53	2.2	156
54	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. <i>Neuro-Oncology</i> , 2006 , 8, 253-60	1	59
53	Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). <i>British Journal of Cancer</i> , 2006 , 95, 1155-60	8.7	193
52	Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2715-22	2.2	583
51	Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. <i>Cancer Treatment Reviews</i> , 2006 , 32, 9-27	14.4	51
50	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. <i>European Journal of Cancer</i> , 2006 , 42, 2499-503	7.5	103
49	Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. <i>British Journal of Cancer</i> , 2006 , 94, 785-91	8.7	67
48	The development of platinum compounds and their possible combination. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 59-75	7	84
47	Novel therapeutics in adult malignant brain gliomas. <i>Expert Opinion on Investigational Drugs</i> , 2005 , 14, 643-58	5.9	4
46	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>New England Journal of Medicine</i> , 2005 , 352, 987-96	59.2	13703

45	Adjuvant chemotherapy in the treatment of high grade gliomas. <i>Cancer Treatment Reviews</i> , 2005 , 31, 79-89	14.4	51
44	Adding temozolomide to radiotherapy prolongs survival in people with glioblastoma. <i>Cancer Treatment Reviews</i> , 2005 , 31, 577-81	14.4	1
43	A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Cancer</i> , 2005 , 104, 143-8	6.4	64
42	Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , 2004 , 22, 4779-86	2.2	101
41	First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1598-604	2.2	83
40	Treatment of brain metastases in uncommon tumors. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 783-93		12
39	Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. <i>British Journal of Cancer</i> , 2004 , 90, 353-8	8.7	108
38	Review of the prognostic factors in medulloblastoma of children and adults. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 50, 121-8	7	43
37	The pathogenesis and treatment of brain metastases: a comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 52, 199-215	7	106
36	A multicenter study of the prognosis and treatment of adult brain ependymal tumors. <i>Cancer</i> , 2004 , 100, 1221-9	6.4	87
35	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. <i>Cancer</i> , 2004 , 101, 2079-85	6.4	35
34	Chemotherapy in brain metastases of lung and breast cancer. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 101-110		
33	Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. <i>Anticancer Research</i> , 2004 , 24, 3221-4	2.3	30
32	Improved tolerability of chemotherapy in soft tissue sarcomas: old and new strategies. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 167-78	3.5	3
31	Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 615-20	3.5	8
30	Introduction: future trends in the treatment of brain tumors. <i>Seminars in Oncology</i> , 2003 , 30, 1-3	5.5	1
29	The treatment of elderly patients with high-grade gliomas. <i>Seminars in Oncology</i> , 2003 , 30, 58-62	5.5	36
28	State-of-the-art treatment of high-grade brain tumors. <i>Seminars in Oncology</i> , 2003 , 30, 4-9	5.5	81

27	A prospective study on glioblastoma in the elderly. <i>Cancer</i> , 2003 , 97, 657-62	6.4	148
26	The treatment of adults with medulloblastoma: a prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 57, 755-61	4	62
25	Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2525-8	2.2	256
24	Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. <i>Oncology</i> , 2002 , 63, 38-41	3.6	51
23	Non-cytotoxic therapies for malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2002 , 58, 57-69	4.8	20
22	Current management and prognostic factors for adult ependymoma. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 537-45	3.5	16
21	Temozolomide in glioblastoma multiforme of the elderly. <i>Tumori</i> , 2002 , 88, S69-70	1.7	
20	Accuracy of technetium-99m sestamibi scintimammography and X-ray mammography in premenopausal women with suspected breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001 , 28, 1776-80	8.8	15
19	Fine-needle aspiration cytology of adrenal masses in noncancer patients: clinicoradiologic and histologic correlations in functioning and nonfunctioning tumors. <i>Cancer</i> , 2001 , 93, 323-9	6.4	66
18	Changing boundaries in the treatment of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 357-70	3.5	6
17	High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. <i>Cancer Investigation</i> , 2001 , 19, 41-8	2.1	16
16	Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. <i>Annals of Oncology</i> , 2001 , 12, 255-7	10.3	68
15	Temozolomide in patients with high grade gliomas. <i>Oncology</i> , 2000 , 59, 181-6	3.6	24
14	Chemotherapy in patients with recurrent and progressive central neurocytoma. <i>Cancer</i> , 2000 , 88, 169-74	6.4	90
13	Endocrine dysfunctions in patients treated for brain tumors: incidence and guidelines for management. <i>Journal of Neuro-Oncology</i> , 2000 , 47, 85-92	4.8	14
12	The treatment of cranial germ cell tumours. <i>Cancer Treatment Reviews</i> , 2000 , 26, 233-42	14.4	60
11	Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. <i>Journal of Clinical Oncology</i> , 1999 , 17, 645-50	2.2	75
10	Medulloblastoma in adults: clinical characteristics and treatment. <i>Cancer Treatment Reviews</i> , 1999 , 25, 3-12	14.4	44

9	Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999 , 22, 387-90	2.7	18
8	Unusual nasal and orbital involvement of glioblastoma multiforme: a case report and review of the literature. <i>Journal of Neuro-Oncology</i> , 1998 , 36, 179-83	4.8	5
7	Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study. <i>Cancer</i> , 1998 , 82, 355-61	6.4	34
6	Treatment of high-grade gliomas in the elderly. <i>Oncology</i> , 1998 , 55, 1-6	3.6	26
5	Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 364-7	2.7	35
4	The role of chemotherapy in recurrent malignant gliomas: an overview. <i>Cancer Investigation</i> , 1996 , 14, 551-9	2.1	58
3	Early chemotherapy and concurrent radio-chemotherapy in high grade glioma. <i>Journal of Neuro-Oncology</i> , 1996 , 30, 247-55	4.8	15
2	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. <i>Cancer</i> , 1990 , 65, 2631-4	6.4	22
1	Cisplatin plus Vindesine versus Cisplatin plus VP16 versus Doxorubicin plus Cytosin in Non-Small-Cell Carcinoma of the Lung. A Randomized Study. <i>Tumori</i> , 1986 , 72, 417-425	1.7	9